Cellular oxygen sensors and other 2-oxoglutarate-dependent enzymes as novel treatment targets for neurological and other diseases

Description of the granted funding

Our objective is to investigate members of the enzyme family of 2-oxoglutarate-dependent dioxygenases (2OGDDs) as novel treatment targets in neurological and other diseases. Especially, we will study activation of the hypoxia response pathway via inhibition of HIF-P4H enzymes – the key cellular oxygen sensors – as a novel concept to protect/treat Alzheimer's disease (AD), the most common form of progressive dementia with no curative treatment, causing huge burden to patients, families and the health care system. Our aim is also to discover the substrate and function of PHYHD1, an uncharacterized 2OGDD that associated with AD in genetic studies, and to exploit our vast experience on enzymology of 2OGDDs to characterize the kinetic and inhibitory properties of PHYHD1 and its structural analogue PHYH, mutated in the neurological Refsum disease. These will produce information of the ability of PHYHD1/PHYH to sense hypoxia and 2-oxoglutarate analogue oncometabolites.
Show more

Starting year

2021

End year

2025

Granted funding

Peppi Karppinen Orcid -palvelun logo
500 000 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

339900

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

brain, neuroscience